Short answer
Boston Scientific (BSX) filed an 8-K current report with the SEC on July 29, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 2.02 (Results of Operations and Financial Condition). Q2 2026 financial results announced for quarter ended June 30, 2026.
Boston Scientific 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 financial results announced for quarter ended June 30, 2026
- Investor-relevant figures and management commentary contained in Exhibit 99.1
- Results update provides the latest view of Boston Scientific’s operating performance and financial condition
Item EX-99.1 · Exhibit EX-99.1
- Q2 net sales $5.442B, up 7.5% reported and 7.0% organic, reaching the top of reported guidance
- GAAP EPS $0.61 and adjusted EPS $0.86, exceeding adjusted guidance of $0.82 to $0.84
- Cardiovascular growth 7.8% organic, outpacing MedSurg at 5.4%, with APAC growth 11.2% and LACA growth 16.2%
- Full-year guidance narrowed to 5.5% to 6.5% reported sales growth and adjusted EPS of $3.28 to $3.32
- $1.5B MiRus investment secured approximately 34% ownership and an exclusive option for its TAVR business, expanding future cardiovascular opportunities
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Boston Scientific 8-K filings
Get the next BSX 8-K as it lands
Follow BSX for push alerts, or ask the research agent what this filing means.